Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) EPS (Weighted Average and Diluted) (2016 - 2025)

Fennec Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 15 years, with the latest figure at -$0.16 for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 100.0% year-over-year to -$0.16, compared with a TTM value of -$0.33 through Dec 2025, down 312.5%, and an annual FY2025 reading of -$0.34, down 1600.0% over the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.16 at Fennec Pharmaceuticals, down from -$0.02 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.41 in Q1 2024, with the low at -$0.31 in Q3 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.13, with a median of -$0.16 recorded in 2021.
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 278.26% in 2024; the steepest drop was 200.0% in 2024.
  • Tracing FENC's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.16 in 2021, then crashed by 56.25% to -$0.25 in 2022, then skyrocketed by 60.0% to -$0.1 in 2023, then rose by 20.0% to -$0.08 in 2024, then plummeted by 100.0% to -$0.16 in 2025.
  • Per Business Quant, the three most recent readings for FENC's EPS (Weighted Average and Diluted) are -$0.16 (Q4 2025), -$0.02 (Q3 2025), and -$0.11 (Q2 2025).